vs
Side-by-side financial comparison of CorMedix Inc. (CRMD) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.
CorMedix Inc. is the larger business by last-quarter revenue ($128.6M vs $71.1M, roughly 1.8× RE/MAX Holdings, Inc.). CorMedix Inc. produced more free cash flow last quarter ($92.7M vs $33.5M).
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
CRMD vs RMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $128.6M | $71.1M |
| Net Profit | — | $1.4M |
| Gross Margin | 83.4% | — |
| Operating Margin | 46.0% | 13.1% |
| Net Margin | — | 2.0% |
| Revenue YoY | — | -1.8% |
| Net Profit YoY | — | -75.2% |
| EPS (diluted) | $0.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $128.6M | $71.1M | ||
| Q3 25 | $104.3M | $73.2M | ||
| Q2 25 | $39.7M | $72.8M | ||
| Q1 25 | $39.1M | $74.5M | ||
| Q4 24 | — | $72.5M | ||
| Q3 24 | — | $78.5M | ||
| Q2 24 | — | $78.5M | ||
| Q1 24 | — | $78.3M |
| Q4 25 | — | $1.4M | ||
| Q3 25 | $108.6M | $4.0M | ||
| Q2 25 | $19.8M | $4.7M | ||
| Q1 25 | $20.6M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | — | $966.0K | ||
| Q2 24 | — | $3.7M | ||
| Q1 24 | — | $-3.4M |
| Q4 25 | 83.4% | — | ||
| Q3 25 | 89.3% | — | ||
| Q2 25 | 95.3% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 46.0% | 13.1% | ||
| Q3 25 | 49.2% | 25.0% | ||
| Q2 25 | 49.2% | 19.3% | ||
| Q1 25 | 51.5% | 7.2% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | — | 19.4% | ||
| Q2 24 | — | 20.6% | ||
| Q1 24 | — | 5.8% |
| Q4 25 | — | 2.0% | ||
| Q3 25 | 104.1% | 5.4% | ||
| Q2 25 | 49.9% | 6.4% | ||
| Q1 25 | 52.8% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | -4.3% |
| Q4 25 | $0.20 | — | ||
| Q3 25 | $1.26 | — | ||
| Q2 25 | $0.28 | — | ||
| Q1 25 | $0.30 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $148.5M | $118.7M |
| Total DebtLower is stronger | — | $432.2M |
| Stockholders' EquityBook value | $405.3M | $452.4M |
| Total Assets | $826.1M | $582.5M |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $148.5M | $118.7M | ||
| Q3 25 | $55.7M | $107.5M | ||
| Q2 25 | $190.7M | $94.3M | ||
| Q1 25 | $77.5M | $89.1M | ||
| Q4 24 | — | $96.6M | ||
| Q3 24 | — | $83.8M | ||
| Q2 24 | — | $66.1M | ||
| Q1 24 | — | $82.1M |
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
| Q4 25 | $405.3M | $452.4M | ||
| Q3 25 | $374.1M | $448.1M | ||
| Q2 25 | $220.6M | $442.4M | ||
| Q1 25 | $114.9M | $433.5M | ||
| Q4 24 | — | $429.5M | ||
| Q3 24 | — | $423.1M | ||
| Q2 24 | — | $418.4M | ||
| Q1 24 | — | $412.0M |
| Q4 25 | $826.1M | $582.5M | ||
| Q3 25 | $750.9M | $582.2M | ||
| Q2 25 | $252.6M | $574.8M | ||
| Q1 25 | $149.6M | $571.4M | ||
| Q4 24 | — | $581.6M | ||
| Q3 24 | — | $578.6M | ||
| Q2 24 | — | $571.4M | ||
| Q1 24 | — | $566.7M |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $94.5M | $40.9M |
| Free Cash FlowOCF − Capex | $92.7M | $33.5M |
| FCF MarginFCF / Revenue | 72.1% | 47.1% |
| Capex IntensityCapex / Revenue | 1.3% | 10.4% |
| Cash ConversionOCF / Net Profit | — | 28.39× |
| TTM Free Cash FlowTrailing 4 quarters | $172.8M | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $94.5M | $40.9M | ||
| Q3 25 | $30.9M | $17.7M | ||
| Q2 25 | $30.0M | $4.6M | ||
| Q1 25 | $19.7M | $5.7M | ||
| Q4 24 | — | $59.7M | ||
| Q3 24 | — | $17.6M | ||
| Q2 24 | — | $15.9M | ||
| Q1 24 | — | $9.4M |
| Q4 25 | $92.7M | $33.5M | ||
| Q3 25 | $30.4M | $16.4M | ||
| Q2 25 | $30.0M | $2.9M | ||
| Q1 25 | $19.7M | $4.0M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $6.8M |
| Q4 25 | 72.1% | 47.1% | ||
| Q3 25 | 29.1% | 22.4% | ||
| Q2 25 | 75.4% | 4.0% | ||
| Q1 25 | 50.5% | 5.3% | ||
| Q4 24 | — | 73.2% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 17.8% | ||
| Q1 24 | — | 8.6% |
| Q4 25 | 1.3% | 10.4% | ||
| Q3 25 | 0.5% | 1.8% | ||
| Q2 25 | 0.1% | 2.2% | ||
| Q1 25 | 0.0% | 2.3% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | — | 28.39× | ||
| Q3 25 | 0.28× | 4.45× | ||
| Q2 25 | 1.51× | 0.97× | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
